Safety and Efficacy of Bortezomib in addition to Adriamycin [doxorubicin] and Intermediate-Dose Dexamethasone (iPAD) in Subjects with Relapse/Refractory Multiple Myeloma with Primary Therapies; A PhaseI/II, Multicentre, Open-Label, Single-Arm Study

Trial Profile

Safety and Efficacy of Bortezomib in addition to Adriamycin [doxorubicin] and Intermediate-Dose Dexamethasone (iPAD) in Subjects with Relapse/Refractory Multiple Myeloma with Primary Therapies; A PhaseI/II, Multicentre, Open-Label, Single-Arm Study

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2011 Status changed from recruiting to completed, according to the University Hospital Medical Information Network - Japan.
    • 27 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top